Navigation Links
Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors

READING, Pa., Sept. 13 /PRNewswire-FirstCall/ -- Arrow International, Inc. (Nasdaq: ARRO) today sent another letter to shareholders urging them to vote today on the WHITE proxy card for its planned $45.50 merger with Teleflex Incorporated (NYSE: TFX) and to re-elect the Arrow Board of Directors, who are committed to completing the Teleflex transaction and delivering $45.50 per share of Arrow common stock to shareholders once the merger is consummated. The Annual Meeting is on September 20, 2007.

The text of the letter follows:

Dear Fellow Arrow Shareholder:

Your vote in support of the merger on the WHITE proxy card is very important

With the Annual Meeting just a week away on September 20, we urge you to vote your WHITE proxy card NOW in support of our $45.50 per share merger with Teleflex. By voting the WHITE proxy card, and voting to approve this transaction and re-elect all of the members of your current Board of Directors, you can help assure that the merger is completed and that you will receive your cash payment.

Your vote to re-elect Arrow's director-nominees is also very important

If you are in favor of the Teleflex merger, we believe it is in your best interests to vote to re-elect your current Board of Directors. These directors are experienced, dedicated and fully committed to completing the Teleflex merger and protecting the interests of all Arrow shareholders. Your current Board of Directors initiated the strategic alternatives process that resulted in the $45.50 per share cash offer from Teleflex.

Do NOT add risk by voting for the McNeil Trust

There is no need to add uncertainty to the merger closing process by electing new directors, as the McNeil Trust is attempting to do. The McNeil Trust opposed the strategic alternatives process from the beginning and voiced support for the merger only after the transaction was publicly announced. There is a difference between being committed to a transaction and merely agreeing to vote for it. We do not think it is in your best interest to allow nominees of a shareholder who is not committed to completing this merger handle any issues that may arise between the approval of the merger agreement and the closing of the transaction. We believe the McNeil Trust's nominees are not the best option for shareholders. We believe their slate presents added risk to the transaction, and in the unlikely event the merger is not consummated, the Trust's slate offers only a return to the disappointments that existed when the current Board of Directors decided to explore strategic alternatives. We strongly urge you NOT to sign or return any blue proxy cards to the McNeil Trust.

Please vote the WHITE proxy card today

If your shares are held by your brokerage firm or bank, you must provide them with instructions on how to vote on your behalf or they will be unable to vote your shares on certain issues, including the adoption of the merger agreement. Given that time is short, we encourage you to follow the instructions on the enclosed form to vote by telephone or Internet.

If you have any questions or would like assistance in voting your shares of Arrow common stock, please call our proxy solicitor, Morrow & Co., Inc., toll-free at 1-800-662-5200.

Sincerely yours,

Philip B. Fleck

President and Chief Executive Officer

R. James Macaleer

Chairman of the Board of Directors

About Arrow

Arrow develops, manufactures and markets a broad range of clinically advanced, disposable catheters and related products for critical and cardiac care. The company's products are used primarily by anesthesiologists, critical care specialists, surgeons, emergency and trauma physicians, cardiologists, interventional radiologists and other healthcare providers. Arrow's news releases and other company information can be found on the World Wide Web at . Arrow's common stock trades on the NASDAQ Global Select Market(TM) under the symbol ARRO.

Additional Information

In connection with the proposed acquisition of Arrow by Teleflex Incorporated and Arrow's 2007 Annual Meeting of Shareholders, Arrow filed a definitive proxy statement with the SEC, on August 24, 2007 and will be filing other documents with the SEC. Arrow has furnished a definitive proxy statement to its shareholders, together with a WHITE proxy card. Arrow shareholders are strongly advised to carefully read Arrow's definitive proxy statement. Shareholders may obtain the definitive proxy statement on file with the SEC and any other documents filed by Arrow with the SEC for free at the internet website maintained by the SEC at . Shareholders may obtain free copies of the definitive proxy statement and any amendments and supplements to the definitive proxy statement at Arrow's website at or by writing to Arrow International, Inc., 2400 Bernville Road, Reading, Pennsylvania 19605. In addition, copies of Arrow's proxy materials may be requested by contacting our proxy solicitor, Morrow & Co. at (800) 662-5200 toll-free or by writing to Morrow & Co., 470 West Avenue, Stamford, CT 06902. Arrow and its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Additional information regarding the names, affiliations and interests of individuals who are participants in the solicitation of proxies of Arrow's shareholders is available in Arrow's definitive proxy statement filed with the SEC on August 24, 2007.

SOURCE Arrow International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Creating brain cells from bone marrow
2. Bone marrow transplants for limbs
3. Bone marrow stem cells may help repair cardiac tissues
4. Bones repair themselves with bone marrow cells
5. Bone Marrow Cells Help Heart Attack Patients
6. Bone Marrow Cells Could Yield A New Lease of Life
7. Stem Cells From Bone Marrow Found To Improve Cardiac Functioning After A Heart Attack
8. Umbilical Cord Blood Offers Hope For Patients Who Require Bone Marrow Transplants
9. Mouth wash samples to predict bone marrow transplant results
10. Stents That Release Medication To Check Artery Narrowing
11. Measuring disseminated cancer cells in bone marrow - valuable tool for detecting early breast cancer metastasis
Post Your Comments:
(Date:11/29/2015)... , ... November 29, 2015 , ... Effective immediately, every ... In addition starting on Black Friday Target is offering a “Buy One Scrub Set, ... is a rare opportunity to purchase IguanaMed at a discounted price. , ...
(Date:11/28/2015)... ... 2015 , ... Safe storage for contraceptive devices may not always be easy ... Jersey and the other from Bradley Beach, New Jersey, there is an easy solution ... having to replace NuvaRings more often than necessary. As such, it affords peace of ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back ... to choose from, the possibilities are endless. Users have full control over angle of ... Pulse masking effects, users are sure to get heads to turn. , ProPanel: Pulse ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... DUBLIN , Nov. 26, 2015 /PRNewswire/ ... announced the addition of the "2016 ... by Test, Country Volume and Sales Segment ... Emerging Opportunities" report to their offering. ... the addition of the "2016 Global ...
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... --> --> Juntendo University ... contrast weighting of MRI for patients with Multiple Sclerosis ... agreement with SyntheticMR in order to use SyMRI in clinical ... to generate multiple contrast images from a single scan and ... making it possible to both fine tune images and recreate ...
Breaking Medicine Technology: